



Aetiology and outcome of generalized convulsive status epilepticus in elderly



Sita Jayalakshmi ^{a,*}, Sudhindra Vooturi ^a, Ramesh Chepuru ^a, Sambit Sahu ^b,
Mohandas Surath ^a

^a Department of Neurology, Krishna Institute of Medical Sciences, Hyderabad, India

^b Department of Intensive Care, Krishna Institute of Medical Sciences, Hyderabad, India

ARTICLE INFO

Article history:

Received 9 January 2015

Received in revised form 25 February 2015

Accepted 17 March 2015

Keywords:

Convulsive status epilepticus

Elderly

Vascular aetiology

Mortality

Outcome

ABSTRACT

Purpose: Convulsive status epilepticus (CSE) is a common neurologic emergency in elderly people. The current study elaborates the clinical characteristics and outcome of CSE in elderly patients.

Methods: Analysis of data of generalized CSE patients, aged 60 years and above admitted at the neurointensive care unit (NICU) was performed. The primary outcome for analysis was in-hospital mortality. The study population was divided into groups based on progression of CSE and mortality to analyze difference in study variables. Mortality of the group was analyzed using life tables.

Results: A total of 33 patients satisfied the inclusion criteria from medical records of 212 patients with CSE. Mean age of the study population was 67.0 ± 6.8 years; 69.7% were men. Acute symptomatic aetiology was the commonest cause of CSE (60.6%); nine (27.3%) patients progressed to refractory status epilepticus (RSE) of which five patients had prolonged RSE. The overall mortality was 18.2%. Complications of mechanical ventilation and mean age were higher in patients who died. Though vascular aetiology was the leading cause of CSE (39.3%), it was not associated with progression to RSE or mortality. Acute symptomatic aetiology accounted for five out of the six deaths in the entire cohort.

Conclusion: Less than one-third of elderly patients with CSE progressed to RSE. Vascular aetiology, the leading cause of generalized CSE in elderly, was not associated with progression to RSE and mortality. Acute symptomatic aetiology was associated with high mortality.

© 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

1. Introduction

Up to 40% of all cases of status epilepticus (SE) have been reported in people aged 60 years and above [1]. In nearly one-third of the older patients, the first seizure presents as SE [2]. The incidence of SE in elderly is almost twice that of general population [3]. The most common aetiology of SE in elderly includes cerebrovascular disease, infection, degenerative disease, neoplasm and trauma [4]. Potential precipitating factors may be inadequate concentrations of antiepileptic medications, alcohol withdrawal, electrolyte imbalances and metabolic derangements [5]. Status epilepticus is nearly five times more common in elderly than young adults [6]. Variations exist in the reported incidence of SE in elderly with studies in Europe reporting an annual incidence of

26.2 per 100,000 people [3]; where as those from the United States report as high as 86 per 100,000 patients aged 60 years and above [1]. Most of the studies included all the types of SE in the analysis. However, little is known about the incidence of convulsive SE (CSE) in elderly among developing countries.

Principles in the treatment of SE in elderly are different from that employed in young adults [7]. In elderly, lower clearance rates and leaner body mass results in higher serum concentrations of anti-epileptic drugs (AEDs) [8]. High prevalence of co-morbid conditions like cardiac disease, hypertension, diabetes among elderly patients with SE is documented [7]. This increases the chance of potential adverse events possibly through alterations in mechanism of AEDs by medications prescribed for co-morbidities [7]. Therefore, the treating physician should consider the circumstances and aetiology. Encouragingly, pharmacotherapy if started promptly, most of the patients respond well and also lowers fatality rate [9].

Mortality due to SE is more common in elderly where people aged between 60 and 79 years and those above 80 years had 36% and 56% higher mortality than those aged under 50 years

* Corresponding author at: Department of Neurology, Krishna Institute of Medical Sciences, 1-8-31/1, Ministers Road, Secunderabad, Telangana, India.

Tel.: +91 9848019036; fax: +91 40 27814499.

E-mail address: sita_js@hotmail.com (S. Jayalakshmi).

[10]. Clinical presentation, age and aetiology strongly predict outcome [3]. Towne et al. [3] have also reported 100% mortality in elderly patients with SE secondary to anoxia, where manifestations of SE are subtle. In patients with ischaemic brain injury, SE is shown to increase mortality by three times [11]. On the contrary, mortality rates are lower in elderly SE patients with aetiology of sub-therapeutic dosages of AEDs [12].

Most of the existing literature on the epidemiology, clinical course and outcome of SE in elderly is from the developed world and includes non-convulsive SE also. However, fastest growth in the older age group has been revealed from both developed and developing countries like India where CSE in elderly is likely to become an important health problem [3,5]. The current study elaborates the clinical characteristics and outcome of CSE in elderly patients.

2. Material and methods

This open cohort was part of a larger epilepsy registry. Analysis of data of elderly patients aged 60 years and above [10] with generalized CSE admitted between May 2005, and November 2014 in the neurointensive care unit (NICU) of Krishna Institute of Medical Sciences, a tertiary care referral centre at Hyderabad in South India was performed. The study was approved after review by the Institutional Ethics Committee.

Patients aged below 60 years of age, those with complex partial SE, absence SE, simple partial SE, myoclonic SE, psychogenic SE, hypoxia related SE and non-convulsive SE were excluded for data analysis. The information about age, gender, duration of CSE, associated co-morbidities, past history of epilepsy and/or CSE was obtained. Aetiology of CSE was classified as acute symptomatic, remote symptomatic, those with pre-existing epilepsy and cryptogenic (cause undetermined) [13]. Acute symptomatic group included patients with central nervous system (CNS) inflammatory disease (presumed encephalitis, CNS infections), acute cerebrovascular CNS disease (ischaemic stroke, cortical sinus venous thrombosis), and those with metabolic aetiologies.

2.1. Definitions

Status Epilepticus was defined as seizures lasting for more than 5 min or recurrent epileptic activity over a period of more than 5 min without regain of pre-existing level of consciousness [1]. Refractory SE (RSE) was defined as SE resistant to one first line, and one second line AED, requiring general anaesthesia (GA) [14]. Prolonged RSE was defined as CSE that continues 24 h or more after the onset of anaesthesia, including those cases in which the CSE recurs on the reduction or withdrawal of anaesthesia [15,16]. If SE recurred days after withdrawal of anaesthetic drugs and warranted re-administration of similar drugs, the length of the NICU stay included the seizure free days too. Presumed encephalitis was defined as encephalopathy (depressed or altered level of consciousness) lasting >24 h with fever, and seizures along with one or more than one of the following symptoms: focal neurological deficits, cerebrospinal fluid (CSF) mononuclear pleocytosis, electroencephalogram (EEG) or neuroimaging findings consistent with encephalitis, after excluding systemic infective causes [17] and metabolic etiologies. All patients had baseline, and follow up CT/MRI brain.

2.2. Treatment

All the patients were treated according to established guidelines [15]. The initial treatment included benzodiazepines (lorazepam or midazolam) followed by intravenous AEDs (phenytoin, phenobarbitone, sodium valproate or levetiracetam alone or

in combination). For GA thiopental, midazolam infusion was used. Continuous EEG monitoring was performed in 28 patients (including all patients who progressed to RSE). Appropriate management of the underlying medical/neurological condition was done.

2.3. Complications and outcome

Severe sepsis, acute kidney injury and acute hepatic failure were defined according to established guidelines [18]. The outcome was classified as death or discharge from the hospital.

2.4. Statistical analysis

After testing for the normal distribution of the data, the study population was divided into two groups based on progression of CSE and mortality. Differences between the groups for continuous variables were analyzed using independent Student's *t*-test, accounting for variance amongst group using Levene's test for equality of variance. Categorical variables were analyzed using chi-square test. A $p < 0.05$ was considered significant. Mortality of the group was analyzed using life tables. Statistical Package for Social Sciences (SPSS, ver. 17.0, IBM computers, New York, USA) was used for all statistical analysis.

3. Results

3.1. Demographic and clinical characteristics

During the study period, a total of 212 patients were admitted to the NICU with a diagnosis of CSE; of which, 33 (15.5%) were patients aged 60 years and above. The mean age of the study population was 67.0 ± 6.8 years; 69.7% were men. Six patients were aged 75 years and above. More than one third of the patients (36.3%) in the study group were known diabetics and nearly half (48.5%) of them were hypertensive. Nine (27.3%) patients progressed to RSE of which five patients had prolonged RSE (Table 1). There were no significant differences between CSE and RSE groups for demographic characteristics (Table 1). However, the mean age of patients who died was higher (65.9 ± 5.9 years vs. 71.8 ± 9.0 years; $p = 0.05$), the differences between groups divided based on mortality is summarized in Table 3.

3.2. Aetiology

Acute symptomatic aetiology accounted for 20 cases (60.6%); five had ischaemic stroke and one patient had cortical venous thrombosis. Thirteen (39.3%) patients had CNS vascular aetiology (ischaemic infarcts in 12 and cortical sinus venous thrombosis in one) and another eight had metabolic aetiology. Six (18.2%) patients had an aetiology of infections of CNS. Focal cerebral calcification and gliosis were observed in one patient each. Amongst the remote symptomatic group, seven patients had vascular aetiology. Aetiology did not differ when the study population was divided into groups based on progression of SE (Table 1) and mortality (Table 3). Acute symptomatic aetiology, did not increase the odds of progression of SE to RSE (OR 1.33, 95% CI 0.28–6.30; $p = 0.509$). Similarly, vascular aetiology also did not increase the odds of progression to RSE (OR 2.96, 95% CI 0.50–17.29; $p = 0.263$).

3.3. Clinical course and complications

In the entire cohort, 12 patients required mechanical ventilation of whom six had evidence of pneumonia. The mean duration of mechanical ventilation was 3.6 ± 6.7 days in the entire cohort. The

Table 1

Comparison of clinical characteristics between groups based on progression of convulsive status epilepticus.

S. No	Variable	RSE (n = 9)	NRSE (n = 24)	p-value
1	Age (Years)	68.3 ± 8.3	66.5 ± 6.3	0.504
2	Men (%)	5 (55.6%)	18 (75.0%)	0.400
3	Hypertensive (%)	6 (66.7%)	10 (41.7%)	0.259
4	Diabetics (%)	2 (22.2%)	10 (41.7%)	0.429
5	Acute symptomatic aetiology (%)	5 (55.6%)	15 (62.5%)	1.000
	Vascular	1 (11.1%)	5 (20.8%)	1.000
	Central nervous system tuberculosis	0 (0.0%)	2 (8.4%)	1.000
	Neurocysticercosis	0 (0.0%)	1 (4.2%)	1.000
	Presumed encephalitis	2 (22.2%)	1 (4.2%)	0.173
	Metabolic	2 (22.2%)	6 (25.0%)	1.000
6	Remote symptomatic aetiology (%)	3 (33.3%)	6 (25.0%)	0.676
	Vascular	1 (11.1%)	6 (0.0%)	0.641
	Focal cerebral calcification	1 (11.1%)	0 (0.0%)	0.272
	Gliosis	1 (11.1%)	0 (0.0%)	0.272
7	Cryptogenic aetiology (%)	1 (11.1%)	0 (0.0%)	0.272
8	Past history of epilepsy present (%)	0 (0.0%)	3 (12.5%)	0.544

RSE – refractory status epilepticus; NRSE – non-refractory status epilepticus.

Table 2

Comparison for clinical course and outcome between groups based on progression of convulsive status epilepticus.

S. No	Variable	RSE (n = 9)	NRSE (n = 24)	p-value
1	Severe sepsis (%)	3 (33.3%)	1 (4.2%)	0.052
2	Acute kidney injury (%)	2 (22.2%)	0 (0.0%)	0.068
3	Acidosis (%)	3 (33.3%)	0 (0.0%)	0.015
4	Duration of mechanical ventilation (No. of days)	10.4 ± 9.3	1.0 ± 2.8	0.017
5	Duration in Neuro intensive care unit (No. of days)	12.8 ± 10.3	4.6 ± 3.4	0.046
6	Duration of hospital stay (No. of days)	16.4 ± 11.2	7.1 ± 3.9	0.039
7	Mortality (%)	4 (44.4%)	2 (8.3%)	0.034

RSE – refractory status epilepticus; NRSE – non-refractory status epilepticus.

duration on mechanical ventilation was higher in patients who progressed to RSE 10.4 ± 9.3 days vs. 1.0 ± 2.8 days; $p = 0.017$). However, duration of mechanical ventilation did not differ between groups based on mortality (2.1 ± 4.3 days vs. 10.3 ± 11.2 days; $p = 0.13$). Patients with RSE had significantly higher incidence of complications of mechanical ventilation like severe sepsis (33.3% vs. 4.2%; $p = 0.052$) and acidosis (33.3% vs. 0.0%; $p = 0.015$), summarized in Table 2. Similarly, complications of mechanical ventilation were higher in patients who died (Table 3). The average length of stay in NICU was higher in RSE patients (12.8 ± 10.3 days vs. 4.6 ± 3.4 days; $p = 0.046$) and those who died (5.6 ± 5.7 days vs. 12.5 ± 9.9 days; $p = 0.029$).

3.4. Outcome and survival analysis

Overall mortality was 18.2%, highest in RSE (44.4% vs. 8.3%; $p = 0.034$). Acute symptomatic aetiology accounted for five out of the six deaths in the entire cohort. Among non-survivors with acute symptomatic aetiology, infections of CNS were observed in three patients. Though vascular aetiology was the leading cause of CSE (39.3%), none of the patients with vascular aetiology died. Five of the six deaths happened in the first 14 days where as the sixth death was reported at the end of fifth week (Fig. 1). In those who survived 15 patients recovered and 12 remained the same at discharge.

Table 3

Comparison between groups based on mortality.

S. No	Variable	Alive (n = 27)	Dead (n = 6)	p-value
1	Age (years)	65.9 ± 5.9	71.8 ± 9.0	0.055
2	Men (%)	21 (77.8%)	2 (33.3%)	0.053
3	Hypertensive (%)	13 (48.1%)	3 (50.0%)	1.000
4	Diabetics (%)	10 (37.0%)	2 (33.3%)	1.000
5	Acute symptomatic aetiology (%)	15 (55.6%)	5 (83.3%)	0.364
6	Remote symptomatic aetiology (%)	8 (29.6%)	1 (16.7%)	1.000
7	Idiopathic aetiology (%)	1 (3.7%)	0 (0.0%)	1.000
8	Known epileptics (%)	3 (11.1%)	0 (0.0%)	1.000
9	Vascular aetiology (%)	13 (29.6%)	0 (0.0%)	0.060
10	Metabolic aetiology (%)	6 (22.2%)	2 (33.3%)	0.616
11	Tuberculosis meningitis (%)	1 (3.7%)	1 (16.7%)	0.335
12	Encephalitis (%)	1 (3.7%)	2 (33.3%)	0.079
13	Refractory status epilepticus (%)	5 (18.4%)	4 (66.7%)	0.034
14	Severe sepsis (%)	1 (3.7%)	3 (50.0%)	0.014
15	Acute kidney injury (%)	0 (0.0%)	2 (33.3%)	0.028
16	Acidosis (%)	0 (0.0%)	3 (50.0%)	0.004
17	Requirement for mechanical ventilation (%)	8 (29.6%)	5 (83.3%)	0.025
18	Duration in Neuro intensive care unit (No. of days)	5.6 ± 5.7	12.5 ± 9.9	0.029
19	Duration of hospital stay (No. of days)	8.8 ± 7.2	13.6 ± 9.7	0.171




Fig. 1. Chronology of deaths.

4. Discussion

The current study evaluates clinical characteristics and outcome of generalized CSE in elderly patients from a developing country. The findings of our study suggest that acute symptomatic aetiology is not only common in elderly patients with CSE but also accounts for most of the deaths. Furthermore, non-survivors have a mean age higher than the survivors. Further research is necessary to evaluate the factors contributing to outcome in elderly patients with CSE.

4.1. Demographic characteristics and aetiology

The prevalence of diabetes mellitus and hypertension in the current study is similar to that reported by Treiman et al., in a multicentre Veteran Affairs study [19]. Consistent with existing evidence [20,21], acute symptomatic aetiology has been the most frequent cause of CSE in the current cohort; furthermore, vascular aetiology followed by metabolic aetiologies were the leading causes of CSE in the current study. The incidence of CSE in patients with acute stroke is similar to that reported in Richmond study [6].

4.2. Clinical course and complications

As anticipated, the duration of stay in the NICU was longer in patients who progressed to RSE, where all RSE patients required mechanical ventilation. Consequently, the complications of mechanical ventilation were higher in patients who progressed to RSE, this is similar to the observations we reported earlier in children and adult patients with CSE [22,23]. However, the duration on mechanical ventilation and duration of hospital stay did not differ between survivors and those who succumbed. This probably may be attributed to our findings that non-survivors had high prevalence of complications of mechanical ventilation and thus leading to early mortality. In developing countries with limited resources, referral to tertiary care centres is often delayed due to failure to recognize early the severity of underlying cause of

CSE and associated injuries. Logistics involved in obtaining the data regarding delay in referral or presentation was out of scope of the current study.

4.3. Outcome and survival analysis

The overall mortality in the current study, done exclusively in elderly patients with generalized CSE was 18.2%. Chin et al. [24] previously reported a short term mortality up to 22% in patients with CSE, with the highest recorded in elderly. In contrast, Sinha et al. [25] reported mortality of 7.9% in elderly patients with new onset SE from India, the study attributed presence of treatable underlying cause and early therapy for reported lower mortalities. Mortality reported previously by larger studies in the developed world were epidemiological studies reported with inclusion of patients with other types of SE like partial SE and non-convulsive SE [10]. Seizure duration is strongly associated with mortality in elderly patients with SE [3].

The current study included elderly patients with generalized CSE only, and was performed in NICU of well-equipped tertiary referral centres, managed by experienced intensivists and senior neurologists, hence early identification of CSE may have helped reduce mortality reported. Our findings of high mortality associated with acute symptomatic aetiology are consistent with those reported by Annergers et al. [10]. Similarly, mortality rates in the current study in patients with metabolic cause is similar to that reported previously [26]. We also report that though vascular aetiology was the leading cause of CSE (39.3%), it did not contribute in progression to RSE, more importantly none of the patients with vascular aetiology died at discharge from hospital. Although these findings are encouraging, evaluation of long term outcomes in elderly patients with CSE due to vascular aetiology are desirable.

Our study reports a higher incidence of RSE, requirement of mechanical ventilation and sepsis in non-survivors, consistent with previous studies that evaluated the affect of infection on mortality and length of stay in intensive care unit among SE patients [27].

4.4. Strengths and limitations

Our study is one of the few series on CSE in elderly patients from the developing world and reflects true clinical practice. However our analysis may have been under powered to detect few associations in individual groups. There may be a selection bias, and under estimation of patients as cases of CSE from NICU only were included in the study and many cases of might have responded well at emergency room. We could not ascertain the exact of duration of CSE prior to admission, as delay in initiation of treatment in SE may influence the duration, and outcome of CSE. Our findings are predominantly single factor association, and should be carefully interpreted; however the findings seem to be clinically plausible.

5. Conclusion

Less than one-third of elderly patients with CSE progressed to RSE. Vascular aetiology, the leading cause of generalized CSE in elderly, was not associated with progression of CSE to RSE and mortality. Acute symptomatic aetiology was associated with high mortality.

Authors' contribution

Study concept and design: Dr. Sita Jayalakshmi; Statistical analysis and interpretation of the data: Dr. Sudhindra Vooturi;

Critical revision of the manuscript: Dr. Surath Mohandas; Data collection and interpretation: Dr. Sambit Sahu, Dr. Ramesh Chepuru, Dr. Sita Jayalakshmi.

Conflict of interest statement

None of the authors have any conflict of interest.

Acknowledgement

None.

References

- [1] Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. *Epilepsia* 1999;40:120–2.
- [2] Cascino GD, Hesdorffer D, Logroscino G, Hauser WA. Morbidity of nonfebrile status epilepticus in Rochester, Minnesota, 1965–1984. *Epilepsia* 1998;39:829–32.
- [3] Towne AR. Epidemiology and outcomes of status epilepticus in the elderly. *Int Rev Neurobiol* 2007;81:111–27.
- [4] Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. *Epilepsia* 1993;34:453–68.
- [5] Waterhouse EJ, DeLorenzo RJ. Status epilepticus in older patients: epidemiology and treatment options. *Drugs Aging* 2001;18:133–42.
- [6] DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. *J Clin Neurophysiol* 1995;12:316–25.
- [7] Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. *Neurology* 2004;62:S24–9.
- [8] Perucca E, Berlowitz D, Birnbaum A, Cloyd JC, Garrard J, Hanlon JT, et al. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. *Epilepsy Res* 2006;68(Suppl. 1):S49–63.
- [9] de Assis TM, Costa G, Bacellar A, Orsini M, Nascimento OJ. Status epilepticus in the elderly: epidemiology, clinical aspects and treatment. *Neurol Int* 2012;4:e17.
- [10] DeLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberthy L, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. *Neurology* 1996;46:1029–35.
- [11] Waterhouse EJ, Vaughan JK, Barnes TY, Boggs JG, Towne AR, Kopec-Garnett L, et al. Synergistic effect of status epilepticus and ischemic brain injury on mortality. *Epilepsy Res* 1998;29:175–83.
- [12] Labovitz DL, Hauser WA, Sacco RL. Prevalence and predictors of early seizure and status epilepticus after first stroke. *Neurology* 2001;57:200–6.
- [13] Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. *Epilepsia* 1993;34:592–6.
- [14] Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. *Arch Neurol* 2002;59:205–10.
- [15] Shorvon S. Super-refractory status epilepticus: an approach to therapy in this difficult clinical situation. *Epilepsia* 2011;52(Suppl. 8):53–6.
- [16] Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. *Brain* 2012;135:2314–28.
- [17] Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. *Lancet Infect Dis* 2010;10:835–44.
- [18] Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med* 2001;29(31):1250–6.
- [19] Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. *N Engl J Med* 1998;339:792–8.
- [20] So EL, Annegers JF, Hauser WA, O'Brien PC, Whisnant JP. Population-based study of seizure disorders after cerebral infarction. *Neurology* 1996;46:350–5.
- [21] Rumbach L, Sablot D, Berger E, Tatu L, Vuillier F, Moulin T. Status epilepticus in stroke: report on a hospital-based stroke cohort. *Neurology* 2000;54:350–4.
- [22] Vooturi S, Jayalakshmi S, Sahu S, Mohandas S. Prognosis and predictors of outcome of refractory generalized convulsive status epilepticus in adults treated in neurointensive care unit. *Clin Neurol Neurosurg* 2014;126:7–10.
- [23] Jayalakshmi S, Ruikar D, Vooturi S, Alladi S, Sahu S, Kaul S, et al. Determinants and predictors of outcome in super refractory status epilepticus – a developing country perspective. *Epilepsy Res* 2014;108:1609–17.
- [24] Chin RF, Neville BG, Scott RC. A systematic review of the epidemiology of status epilepticus. *Eur J Neurol* 2004;11:800–10.
- [25] Sinha S, Satishchandra P, Kalband BR, Thennarasu K. New-onset status epilepticus and cluster seizures in the elderly. *J Clin Neurosci* 2013;20:423–8.
- [26] DeLorenzo RJ, Towne AR, Pellock JM, Ko D. Status epilepticus in children, adults, and the elderly. *Epilepsia* 1992;33(Suppl. 4):S15–25.
- [27] Sutter R, Tschudin-Sutter S, Grize L, Fuhr P, Bonten MJ, Widmer AF, et al. Associations between infections and clinical outcome parameters in status epilepticus: a retrospective 5-year cohort study. *Epilepsia* 2012;53:1489–97.